Production (Stage)
Protara Therapeutics, Inc.
TARA
$3.34
$0.2156.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.93% | -10.33% | 39.21% | 39.27% | 33.89% |
| Total Depreciation and Amortization | -4.32% | -2.64% | 15.53% | 19.73% | 29.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.09% | -33.21% | -85.70% | -84.64% | -83.60% |
| Change in Net Operating Assets | 12.98% | 196.81% | 189.05% | 142.45% | 136.63% |
| Cash from Operations | -14.53% | 4.66% | -3.89% | -2.01% | -23.48% |
| Capital Expenditure | -174.36% | -40.00% | -23.53% | 5.15% | 66.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -193.68% | -63.84% | -44.64% | 42.48% | 174.55% |
| Cash from Investing | -193.90% | -63.93% | -44.81% | 42.62% | 175.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -86.41% | 8.79% | 8.79% | -34.15% | -25.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 137,644.66% | 153,797.80% | 46,271.43% | 51,306.10% | -25.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.75% | 697.02% | 231.02% | 34,012.27% | 808.84% |